Skip to main content
Premium Trial:

Request an Annual Quote

Publicly Traded RNAi Drug Firms


With Rosetta Genomics prepping for an initial public offering during this year or next, it is set to join a handful of other companies in the RNAi drugs game that are traded on public markets. To date Alnylam Pharmaceuticals is the only firm to have floated its shares as an RNAi company; all the others were already public when they reorganized to focus on the gene-silencing technology.

Below is a breakdown of the public companies in the space.

Publicly Traded RNAi Drug Firms
Ticker Symbol
Date Founded
Date of IPO/Date Began Trading as RNAi Firm
Stock Price at IPO/Stock Price after Becoming RNAi Firm
Current Stock Price (as of Jan. 26)
Alnylam Pharmaceuticals ALNY July 2002 May 2004
Benitec BLT.AX February 1997 as Queensland Opal, an opal mining concern. Reorganized into RNAi firm in July 2002. Shares began trading on Australian Stock Exchange under Benitec name in July 2002.
CytRx CYTR February 1985. Began researching RNAi in April 2003 after corporate reorganization. Began trading as RNAi company in April 2003.
Genesis Research and Development GEN.AX September 2000. Shifted focus onto RNAi therapeutics around December 2003. Began trading on Australian Stock Exchange with new RNAi focus around December 2003.
Sirna Therapeutics RNAI January 1992. Changed name to Sirna Therapeutics from Ribozyme Pharmaceuticals, and shifted focus onto RNAi in April 2003. Began trading as Sirna Therapeutics in April 2003.
SR Pharma SPA.L November 1994. Began researching RNAi therapeutics after July 2005 acquisition of Atugen. Began trading on the London Stock Exchange with an RNAi focus in July 2005.
The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.